Patents by Inventor Yoshiko Kita
Yoshiko Kita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8444990Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.Type: GrantFiled: October 8, 2010Date of Patent: May 21, 2013Assignee: Amgen Inc.Inventors: Tsutomu Arakawa, Yoshiko Kita
-
Patent number: 8076449Abstract: The present invention relates to a pharmaceutical composition for the treatment and/or prevention of a neurodegenerative disease, comprising the following polypeptide shown in any of (a) to (c): (a) a polypeptide comprising the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1); (b) a polypeptide comprising an amino acid sequence having a deletion, substitution, insertion, and/or addition of one or several amino acids in the amino acid sequence consisting of Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death associated with neurodegenerative disease; and (c) a modified polypeptide from the polypeptide (a) or (b), or a pharmaceutically acceptable salt thereof, as an effective ingredient.Type: GrantFiled: April 8, 2005Date of Patent: December 13, 2011Assignees: Tomohiro Chiba, Massaaki Matsuoka, Kenzo Terashita, Sadakazu Also, Tomo NishimotoInventors: Tomohiro Chiba, Yoshiko Kita, Masaaki Matsuoka, Kenzo Terashita, Sadakazu Aiso, Ikuo Nishimoto, Tomo Nishimoto, legal representative
-
Publication number: 20110189168Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.Type: ApplicationFiled: October 8, 2010Publication date: August 4, 2011Inventors: Tsutomu Arakawa, Yoshiko Kita
-
Publication number: 20100279942Abstract: An object of the present invention is to provide an agent effective for the treatment and/or prevention of motor neuron disease such as amyotrophic lateral sclerosis (ALS). The present invention provides a therapeutic and/or preventive agent for motor neuron disease comprising the following oligopeptide shown in any of (a) to (c) or a pharmaceutically acceptable salt thereof as an active ingredient: (a) an oligopeptide consisting of the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1); (b) an oligopeptide consisting of an amino acid sequence having a deletion, substitution, insertion, or addition of one or several amino acids in Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death caused by a mutant superoxide dismutase-1 gene; and (c) a modified oligopeptide from the oligopeptide (a) or (b).Type: ApplicationFiled: April 7, 2010Publication date: November 4, 2010Inventors: TOMOHIRO CHIBA, YOSHIKO KITA, MASAAKI MATSUOKA, KENZO TERASHITA, SADAKAZU AISO, IKUO NISHIMOTO, TOMO NISHIMOTO
-
Patent number: 7811566Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.Type: GrantFiled: October 30, 2007Date of Patent: October 12, 2010Assignee: Amgen, Inc.Inventors: Tsutomu Arakawa, Yoshiko Kita
-
Publication number: 20090142359Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.Type: ApplicationFiled: October 30, 2007Publication date: June 4, 2009Inventors: Tsutomu Arakawa, Yoshiko Kita
-
Publication number: 20090075900Abstract: An object of the present invention is to provide an agent effective for the treatment and/or prevention of motor neuron disease such as amyotrophic lateral sclerosis (ALS). The present invention provides a therapeutic and/or preventive agent for motor neuron disease comprising the following oligopeptide shown in any of (a) to (c) or a pharmaceutically acceptable salt thereof as an active ingredient: (a) an oligopeptide consisting of the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1); (b) an oligopeptide consisting of an amino acid sequence having a deletion, substitution, insertion, or addition of one or several amino acids in Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death caused by a mutant superoxide dismutase-1 gene; and (c) a modified oligopeptide from the oligopeptide (a) or (b).Type: ApplicationFiled: December 8, 2004Publication date: March 19, 2009Applicants: Sadakazu, NOEVIR CO., LTD.Inventors: Sadakazu Aiso, Masaaki Matsuoka, Tomohiro Chiba, Yoshiko Kita, Kenzo Terashita
-
Publication number: 20080227699Abstract: The present invention relates to a pharmaceutical composition for the treatment and/or prevention of a neurodegenerative disease, comprising the following polypeptide shown in any of (a) to (c): (a) a polypeptide comprising the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1); (b) a polypeptide comprising an amino acid sequence having a deletion, substitution, insertion, and/or addition of one or several amino acids in the amino acid sequence consisting of Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death associated with neurodegenerative disease; and (c) a modified polypeptide from the polypeptide (a) or (b), or a pharmaceutically acceptable salt thereof, as an effective ingredient.Type: ApplicationFiled: April 8, 2005Publication date: September 18, 2008Inventors: Tomohiro Chiba, Yoshiko Kita, Masaaki Matsuoka, Kenzo Terashita, Sadakazu Aiso, Ikuo Nishimoto, Tomo Nishimoto
-
Patent number: 7354583Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.Type: GrantFiled: November 27, 2001Date of Patent: April 8, 2008Assignee: Amgen, Inc.Inventors: Tsutomu Arakawa, Yoshiko Kita
-
Publication number: 20020164334Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.Type: ApplicationFiled: November 27, 2001Publication date: November 7, 2002Applicant: Amgen Inc.Inventors: Tsutomu Arakawa, Yoshiko Kita
-
Patent number: 6458356Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to “tag” Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.Type: GrantFiled: March 23, 1998Date of Patent: October 1, 2002Assignee: Amgen Inc.Inventors: Tsutomu Arakawa, Yoshiko Kita
-
Patent number: 5783186Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to "tag" Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.Type: GrantFiled: December 5, 1995Date of Patent: July 21, 1998Assignee: Amgen Inc.Inventors: Tsutomu Arakawa, Yoshiko Kita